Product Datasheet

CPI-203

Catalog No. **BP-02124** · CAS **1446144-04-2** · Form **free base** · Physical state **solid** · Color **Light yellow to yellow** · Version **1.0** · Revision **2026-09-02**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
Epigenetic Reader Domain; Apoptosis	**Cancer**

Molecular formula	**$C_{19}H_{18}ClN_5OS$**
Molecular weight	**399.8970**

STRUCTURE



DESCRIPTION

CPI-203 is a novel potent, selective and cell permeable inhibitor of BET bromodomain, with an IC50 value of appr 37 nM (BRD4 α-screen assay).

BIOLOGICAL ACTIVITY

In Vitro

CPI-203 inhibits BRD4 in vitro and in cells, but does not affect BRD4 kinase activity in vitro[1]. CPI-203 exerts a cytostatic effect in all the 9 MCL cell lines analyzed with GI50 ranging from 0.06 to 0.71 μM, with low cytotoxicity in normal PBMCs from healthy donors. Furthermore, CPI-203 efficiently activates the cell death program in MCL cells.

In Vivo

CPI-203 (2.5 mg/kg, i.p.) combined with lenalidomide, enhances the antitumoral properties of each single agent via the abrogation of MYC and IRF4 expression and the induction of apoptosis in n REC-1 tumor-bearing mice.

SOLUBILITY

Soluble in DMSO

REFERENCES

[1]. Devaiah BN, et al. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci U S A. 2012 May 1;109(18):6927-32.

[2]. Moros A, et al. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia. 2014 Oct;28(10):2049-59.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com